CAZZANIGA GIOVANNI
Biography
EDUCATION
2021 - Associate Professor, Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.
2018 - Assistant Professor (Ricercatore a Tempo Determinato di tipo B, RTDB), Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.
2014 - Qualification (National Scientific Habilitation, ASN) for Associate Professorship to the following sections: 05/F1 Applied Biology BIO/13 and 06/A1 Medical Genetics MED/03, 06/A2 General and Clinical Pathology (deadline 07/01/2023).
2004 - Specialist in Medical Genetics. Faculty of Medicine, University of Milan, Italy. 70/70 cum laude.
1992 - Specialist in Pharmaceutical Research at the “M.Negri” Pharmacology Research Institute of Milan, Italy.
1990 - Biological Science degree at the University of Milan, Italy. 110/110 cum laude.
PROFESSIONAL POSITION
05/2023 - now: Acting Director (ff), Medical Genetics, Foundation IRCCS San Gerardo dei Tintori, Monza, Italy
03/2023 - now: Deputy Director, Ph.D. Program in Translational and Molecular Medicine (Dimet), University of Milan Bicocca.
12/2021 - now: Associate Professor, Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.
2006 - now: Head, “Molecular genetics of leukemia” Unit, Centro Tettamanti, Fondazione Tettamanti, Monza, Italy.
2018-2021: Assistant Professor (Ricercatore a Tempo Determinato di tipo B, RTDB), Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.
2009 - 04/2023: Director, Laboratory of Hemato-Oncology Diagnostics “M. Tettamanti”, Fondazione MBBM, Monza.
1995/1997: Research fellow at the “M.Tettamanti” Research Center, Pediatric Clinic, University of Milan-Bicocca, Ospedale San Gerardo, Monza, Italy.
1990/1994: Research fellow at the Laboratory of Enzymology - Molecular Biology Unit - "M.Negri" Pharmacology Research Institute, Milan, Italy.
Research
MAJOR RESEARCH INTERESTS
- Genetic predisposition to childhood acute lymphoblastic leukemia (ALL)
- Prenatal origin of ALL
- Molecular characterization of childhood ALL
- Functional analysis of genetic aberrations in leukemic patients (PAX5 lesions, Ph-like ALL, Down Syndrome ALL, MLL-rearrangements) and in vitro/in vivo drug targeting
- Minimal residual disease monitoring in childhood ALL, by analysis of T-cell Receptor and Immunoglobulin genes’ rearrangements.
Publications
Crespiatico, I., Zaghi, M., Mastini, C., D'Aliberti, D., Mauri, M., Mercado, C., et al. (2024). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. BLOOD [10.1182/blood.2023021349]. Detail
Elli, E., Mauri, M., D’Aliberti, D., Crespiatico, I., Fontana, D., Redaelli, S., et al. (2024). Idiopathic erythrocytosis: a germline disease?. CLINICAL AND EXPERIMENTAL MEDICINE, 24(1) [10.1007/s10238-023-01283-y]. Detail
Bomken, S., Enshaei, A., Schwalbe, E., Mikulasova, A., Dai, Y., Zaka, M., et al. (2023). Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. HAEMATOLOGICA, 108(3 (March, 2023)), 717-731 [10.3324/haematol.2021.280557]. Detail
Barone, C., Orsenigo, R., Cazzola, A., D'Errico, E., Patelli, A., Quattrini, G., et al. (2023). Hematopoietic Stem Cell (HSC)-Independent Progenitors Are Susceptible to Mll-Af9-Induced Leukemic Transformation. CANCERS, 15(14) [10.3390/cancers15143624]. Detail
Saettini, F., Guerra, F., Fazio, G., Bugarin, C., Mcmillan, H., Ohtake, A., et al. (2023). Correction to: Antibody Deficiency in Patients with Biallelic KARS1 Mutations (Journal of Clinical Immunology, (2023), 43, 8, (2115-2125), 10.1007/s10875-023-01584-7) [Altro] [10.1007/s10875-023-01600-w]. Detail